Abstract
Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes virus which establishes a life-long asymptomatic infection in immunocompetent hosts. In human immunodeficiency virus type 1 (HIV-1) infected patients, the impaired immunosurveillance against EBV may favor the development of EBV-related diseases, ranging from lymphoproliferative disorders to B cell non-Hodgkin’s lymphomas (NHL). Antiretroviral therapy (ART) has significantly modified the natural course of HIV-1 infection, resulting in decreased HIV-1 plasmaviremia, increased CD4 lymphocytes, and decreased opportunistic infections, indicating a restoration of immune functions. However, the impact of ART appears to be less favorable on EBV-related malignancies than on other AIDS-defining tumors, such as Kaposi’s sarcoma, and NHL remains the most common cancer during the ART era. EBV-driven tumors are associated with selective expression of latent oncogenic proteins, but uncontrolled lytic cycle with virus replication and/or reactivation may favor cell transformation, at least in the early phases. Several host’s factors may promote EBV reactivation and replication; besides immunodepression, inflammation/chronic immune stimulation may play an important role. Microbial pathogen-associated molecular patterns and endogenous damage-associated molecular patterns, through Toll-like receptors, activate the immune system and may promote EBV reactivation and/or polyclonal expansion of EBV-infected cells. A body of evidence suggests that chronic immune stimulation is a hallmark of HIV-1 pathogenesis and may persist even in ART-treated patients. This review focuses on lymphomagenesis driven by EBV both in the context of the natural history of HIV-1 infection and in ART-treated patients. Understanding the mechanisms involved in the expansion of EBV-infected cells is a premise for the identification of prognostic markers of EBV-associated malignancies.
INTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous human γ-herpes virus which establishes a life-long asymptomatic infection in immunocompetent hosts. Most individuals contract EBV infection by early adulthood; primary EBV infection is usually asymptomatic, but sometimes results in infectious mononucleosis, a self-limiting disease due to the EBV-specific immunological response. Regardless of its iatrogenic or infectious origin, immunodeficiency increases the risk of tumor development, particularly of tumors etiologically linked to viral agents. In post-transplant patients and in individuals infected with human immunodeficiency virus type 1 (HIV-1), impaired immunosurveillance against EBV may favor the development of EBV-associated diseases, ranging from lymphoproliferative disorders to B cell non-Hodgkin’s lymphomas (NHL; ; ). Antiretroviral therapy (ART) partially restores immune functions and has significantly changed the course of HIV-1 infection (). However, the impact of ART seems to be less favorable on EBV-related diseases than on other AIDS-defining events, including Kaposi’s sarcoma (KS; Simard et al., 2011). Notably, NHL has been considered as an AIDS-defining cancer (ADC) since 1985, and remains one of the main causes of death in HIV-1 infected patients even in the ART era [; Simard et al., 2011].
INCIDENCE OF EBV-RELATED MALIGNANCIES IN HIV-1 INFECTED PATIENTS
There are several subtypes of AIDS-associated NHL, including Burkitt’s lymphoma (BL), immunoblastic lymphoma (IBL), diffuse large B cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNSL). The frequency of EBV detection in these tumors ranges from 60% in BL to 100% in PCNSL (). Before the introduction of ART, the incidence of NHL in HIV-1 infected subjects was 100 times higher than in the general population (; ), PCNSL and high grade IBL being the most common NHL subtypes, followed by BL and intermediate grade DLBCL ().
High levels of HIV-1 plasmaviremia and low CD4 cell counts are both risk factors for the onset of NHL. The risk substantially increases in patients with >100,000 HIV-1 RNA copies/ml and/or with <50 CD4 cells/μl (). However, systemic lymphomas may occur at virtually any level of CD4 cell count, BL occurring more frequently in patients with moderate/advanced immunodepression (200–500 CD4 cells/μl) and PCNSL occurring in patients with severe immunodepression (<200 CD4 cells/μl).
The introduction of ART into clinical practice has modified the natural course of HIV-1 infection, resulting in the decrease of HIV-1 plasmaviremia, increase in CD4 T lymphocytes, and decrease in HIV-1-associated opportunistic infections. Deaths from AIDS-related diseases have fallen by 75% (Tirelli and Bernardi, 2001) and people diagnosed with HIV-1 can expect to live for 30 or 40 years after contracting the infection, equivalent to a reduction in lifespan of about one-third (). Therefore, patients with HIV-1 infection are now living longer, with improved immune functions and reduced risk of developing AIDS; nevertheless, ADCs remain higher when compared with the rate of these cancers in the general population ().
After the introduction of ART, the overall incidence of NHL declined by nearly 50% compared with ART-untreated patients (; ; Simard et al., 2011); the adjusted incidence rate of NHL was estimated to decline from 6.2% pre-ART (1992–1999) to 3.2% in the ART era (1997–1999; ). Five-year cumulative incidence of NHL declined from 3.8% during the 1990–1995 period to 2.2% during 1996–2006 (Simard et al., 2011). This pattern is quite different from that observed with KS, associated with human herpes virus 8 (HHV8; ; Simard et al., 2011). The adjusted incidence rate of KS declined from 14.3% pre-ART to 1.8% in the ART era (Simard et al., 2011). After the introduction of ART, NHL is still the most common ADC. In addition, the decline is not equally distributed among the various NHL subtypes, but is higher for PCNSL and lower for the other subtypes.
The increased risk of NHL cannot be explained by immunodepression alone. Patients treated with ART may survive longer, with continued B cell stimulation, leading to an increased incidence of lymphoma over time. Emerging data also indicate that HIV-1 infection, even among long-term ART-treated patients, is associated with a higher rate of non-AIDS-defining malignancies (NADC; ); this evidence further supports the concept that immunodeficiency is not sufficient to explain the higher risk of cancer in HIV-1 infected subjects. The substantial reduction in HIV-1-associated mortality and the increase in an aging population with HIV-1 may contribute to the rise in NADC, including some tumors associated with co-infections [e.g., anal and oropharyngeal cancer associated with human papillomavirus, liver cancer associated with hepatitis B and C viruses, and Hodgkin’s lymphoma (HL) associated with EBV]. In a cohort of HIV-1 infected European patients, the incidence of HL was 4.5 times higher than in the general population pre-ART (1983–1985) and 32 times higher in the ART era (2002–2007; Powles et al., 2009). These results have been replicated in a Swiss HIV-1 cohort, in which the incidence of HL increased 9 times pre-ART, 21 times in the early ART era, and 28 times in the late ART era (). Also, in a United States cohort, the 5-year cumulative incidence of HL increased from 0.09% pre-ART (1980–1989) to 0.19% in the ART era (1996–2006; Simard et al., 2011). HIV-1-associated HL differs from HL in HIV-1 uninfected patients, because it is almost always associated with EBV and more often presents systemic “B” symptoms, and extranodal involvement ().
EBV-DRIVEN TUMORIGENESIS
Epstein–Barr virus is associated with both B cell and epithelial cell malignancies. Like all herpes viruses, EBV has both latent and lytic replication programs, allowing it to evade immune clearance and persist for the host’s lifetime. Latent infection is characterized by replication of the viral genome as an integral part of the host cell chromosomes and the absence of production of infectious virus. Since lytic EBV replication triggers the death of infected cells, tumors require the expression of latent programs. Latent proteins include nuclear antigens (EBNA-1, -2, -3A, -3B, and -3C), leader protein (LP), and latent membrane proteins (LMP-1, -2A, and -2B). LMP-1 is the main oncogenic protein of EBV and is essential for EBV-driven tumorigenesis. It is expressed in all NHL, except BL, and also in HL. Functionally, LMP-1 mimics CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, thus providing both growth and differentiation signals to B cells. LMP-1 does in fact activate several downstream signaling pathways which contribute to the induction of genes encoding anti-apoptotic proteins (e.g., BCL-2 and A20) and cytokines, such as interleukin (IL)-1, and CD40L (Young and Rickinson, 2004; ).
In vitro, EBV infection of B cells may generate immortalized lymphoblastoid B cell lines (LCL) which express all the latent viral genes, as most EBV-NHL do; this is why LCL are often employed as a model to study EBV-driven lymphomagenesis. Besides the expression of viral latent proteins, the transformation of primary B lymphocytes by EBV requires the activation of telomerase (). Telomerase is a ribonucleoprotein complex, containing an internal RNA, used as a template to elongate telomeres, and a catalytic protein with telomerase reverse transcriptase (TERT) activity. Telomerase is critically involved in maintaining telomere length and its activation is required for cells to overcome replicative senescence and acquire unlimited replicative potential, a prerequisite for neoplastic transformation (). It has been demonstrated that LMP-1 activates TERT at transcriptional level via nuclear factor kappa B (NF-κB) and MAPK/ERK1/2 pathways (Terrin et al., 2007, 2008). In turn, TERT expression confers resistance to apoptotic stimuli and to the induction of the lytic cycle ().
Although latency programs predominate in EBV-driven tumors, recent evidence suggests that lytic EBV replication has some pathogenic importance, at least in the early phases of cell transformation. Several lytic proteins expressed during the lytic cycle of infection are involved in immune evasion. They include the BCRF-1 gene which encodes a viral IL-10 cytokine which, like human IL-10, inhibits the synthesis of interferon-γ (IFN-γ) and suppresses CD8 cytotoxic T cell (). Recent studies also suggest that the lytic cycle contributes to the growth of EBV-associated malignancies by enhancing angiogenesis. Indeed, B cells infected with a virus competent for the expression of the lytic protein BZLF-1 released more vascular endothelial growth factor and IL-6 than cells infected with BZLF-1-defective virus (). A new humanized mouse model, in which both human fetal CD34 hematopoietic stem cells and thymus/liver tissue were transplanted, was employed to test EBV-driven lymphomagenesis; mice injected with lytic replication-defective BZLF1-deleted virus developed fewer lymphomas than animals infected with lytic BZLF1-competent virus, suggesting that lytically infected cells promote EBV-driven lymphomagenesis ().
DIRECT AND INDIRECT INTERACTIONS OF HIV-1 WITH B CELLS AND EBV
Besides impaired immunosurveillance against EBV-infected cells due to the loss of T cell function, HIV-1 may contribute to the genesis of EBV-associated NHL through chronic B cell hyperactivation. Chronic systemic immune activation is a hallmark of HIV-1 pathogenesis; being one of the strongest predictors of disease progression (; ) and it is also associated with impaired immune reconstitution during ART ().
Immune activation involves both T cell and B cell compartments. In the former, immune activation may be assessed by the high frequency of T cells expressing markers of activation, such as CD38 and HLA-DR (; ), high levels of T cell proliferation (), and activation-induced apoptosis of HIV-1 uninfected T cells (). In the B cell compartment, B cells express high levels of CD80 and CD86 co-stimulatory molecules. Several changes in the B cell subsets have also been described in association with HIV-1 plasmaviremia and/or CD4 cell decline. These changes include an increase in activated (CD27+CD21low) and exhausted (CD27-CD21low) B cells (), a decrease in circulating memory (CD27+) B cells (Titanji et al., 2006), and an increase in immature/transitional (CD27-CD10+) B cells (). Immune activation may result in polyclonal B cell activation, hypergammaglobulinemia, increased cell turnover (), and ultimately increased frequency of B cell malignancies ().
The factors contributing to B cell hyperactivation and expansion of EBV-infected B cells remain largely unknown. The mechanisms responsible for polyclonal B cell activation seem to be multiple, and due to a combination of both direct and indirect interaction of B cells with HIV-1. HIV-1 itself can induce polyclonal B cell activation in vitro (). It has been demonstrated that CD40L is incorporated into the HIV-1 envelope (), and that B cells derived from the peripheral blood of HIV-1 infected viremic patients carry replication-competent virus on their membrane (). There is evidence that HIV-1 binds to B cells through interactions between the complement receptor CD21, which is expressed on most mature B cells (); the virus bound to B cells can efficiently infect CD4 T cells through cell–cell contact (). A model of “self-limiting” HIV-1 infection of B cells has been described. After in vitro exposure to HIV-1, a steady-state fraction of LCL resulted positive for HIV-1 gp120 envelope protein. These cells underwent down-regulation of BCL-2 and death by apoptosis; the persistent fraction of gp120+ cells was maintained by HIV-1 transmission to B cells newly arising from the proliferation of gp120- cells (). It was also demonstrated that a fraction of B cells may bind gp120 through mannose C-type lectin receptors (MCLRs). In the presence of gp120, MCLR-expressing B cells up-regulate the activation-induced cytidine deaminase, and undergo immunoglobulin class switching (). By contrast, HIV-1 protein Nef suppresses class switch recombination on B cells by interfering with CD40L-mediated signaling (). Nef also promotes polyclonal B cell activation and increases CD4 T cell susceptibility to HIV-1 infection by inducing macrophages to secrete pro-inflammatory cytokines (Swingler et al., 2008). Additional in vitro evidence of direct interaction between HIV-1 and several receptors on B cells have been reported (; ), however, to date there is still little evidence that HIV-1 can productively replicate in B cells in vivo.
The transactivator Tat protein of HIV-1 is released by HIV-1 infected cells and is taken up by surrounding HIV-1-uninfected cells through interactions with cell membrane heparan sulfate proteoglycans (; Tyagi et al., 2001). HIV-1 binds to B cells which are in close contact with HIV-1-infected macrophages and to dendritic cells in the extranodal sites where NHL usually occur (Sparano, 2001). This cell–cell contact may favor B cell uptake of the protein; Tat protein has in fact been consistently detected in the neoplastic cells of NHL occurring in HIV-1 infected subjects (). Tat modulates the expression of several cellular genes, including cytokines and their receptors, and increases the expression of IL-6 and IL-10 (; ), which in turn promote B cell activation. It has been demonstrated that Tat prevents cell cycle arrest and confers resistance to apoptosis in EBV-infected B cells cultured in vitro in serum starvation conditions ().
Chronic B cell hyperactivation is driven by overproduction of B cell stimulatory cytokines, such as IL-6, IL-10, interferon-α (IFN-α), and tumor necrosis factor (TNF; ; Takeshita et al., 1995; ). The serum levels of these B cell stimulatory cytokines and other molecules, such as soluble sCD27 and sCD30 generated from the corresponding B cell receptors during the process of immune activation, were significantly high 1–5 years prior to diagnosis of systemic AIDS-NHL (; ). Elevated serum levels of IL-6 have also been observed 1–3 years prior to the onset of AIDS-NHL, thus supporting the role of IL-6-driven B cell stimulation in the development of these lymphomas ().
Lastly, an important source of immune activation in HIV-1 infected individuals is provided by microbial translocation due to damage to intestinal mucosa caused by massive HIV-1-induced T cell depletion in the gut (). Translocation of intestinal bacteria and bacterial products into the bloodstream can activate the immune system by binding to receptors involved in the host inflammatory response, such as Toll-like receptors (TLRs). TLRs are pattern recognition receptors which recognize structural components belonging to bacteria, fungi, and viruses, known as “pathogen-associated molecular patterns” (PAMPs), and activate the innate immune response (). PAMPs include bacterial lipopolysaccharide (LPS), 16S ribosomal DNA (16S rDNA), and CpG DNA. A recent study demonstrated that levels of PAMPs, generated by microbial translocation (sCD14 and LPS) are associated with the risk of NHL (). TLR9 substantially suppresses BZLF-1-mRNA expression by histone modifications in acute EBV infection ex vivo and in latently BL cells in vitro, suggesting that immune activation can also promote EBV-driven lymphomagenesis by suppressing the viral lytic cycle (). Patients who developed PCNSL expressed more CD80 and CD86 in their B cells and responded to TLR9 agonist better than patients without tumors ().
The loss of mucosal surface integrity in the gut, due to the massive depletion of CD4 T cells, involves not only increased mucosal permeability and consequent microbial translocation, but also an increase in “damage-associated molecular patterns” (DAMPs), endogenous molecules released after cell death, such as mitochondrial DNA (mtDNA; Zhang et al., 2010), high mobility group box 1 (HMGB1) protein () and defensins (Sørensen et al., 2005). The binding of PAMP and DAMP ligands to the extra- or intra-cellular domain of TLRs initiates a complex-signal transduction cascade which, via the NF-κB pathway, ultimately leads to increased transcription of pro-inflammatory cytokines, such as IL-6 and TNF. During chronic infection, PAMPs and DAMPs may act in synergy on the TLR response. Thus, chronic inflammation may favor an environment which triggers tumor development.
IMPACT OF ANTIRETROVIRAL THERAPY ON EBV LYMPHOMAGENESIS
The impact of ART is less favorable on EBV-related malignancies than on other ADC. In addition, the decline after the introduction of ART was more substantial in PCNSL than in other NHL subtypes. Because of the role played by chronic immune activation in the genesis of NHL, it may be argue that this mechanism (partially) persists even during ART. A study performed on a cohort of HIV-1-infected patients under ART disclosed a decline in both EBV plasmaviremia and citoviremia in patients with immunological (increase in CD4 cells) and virological (decline in HIV-1 plasmaviremia to undetectable levels) responses. Notably, a decrease in EBV load was also detected in patients with only virological response to ART. By contrast, the increase in CD4 cells without suppression of HIV-1 plasmaviremia was accompanied by an increase in EBV load, paralleled by an increase in immunoglobulin levels (). In agreement, EBV-DNA load was higher in patients with detectable HIV-1 plasmaviremia, despite good immunological status (>500 CD4 cells/μl) than in patients with undetectable HIV-1 plasmaviremia, regardless of immunological status (). It has been observed that ART only partially normalizes the serum cytokine levels; IL-6 remain at high levels even 2–3 years after ART initiation (). These findings strongly suggest that immune reconstitution without reduction in HIV-1 viremia may increase B cell stimulation and the number of EBV-infected cells; this may be important for new therapeutic strategies against HIV-1 to implement immune reconstitution and/or to alleviate adverse drug effects.
HIV-1 infected patients, treated with ART in combination with IL-2 to improve immunological reconstitution, showed a decrease in EBV plasmaviremia and citoviremia when treated with low-intermittent IL-2 doses, but presented an increase in EBV in both cells and plasma when treated with high doses of IL-2 (). Thus, according to dose, IL-2 may significantly affect EBV dynamics. Low doses of IL-2, by binding to high-affinity receptors expressed on T lymphocytes, may promote the activity of cytotoxic T lymphocytes, thus restoring protective immunity against EBV. Notably, low doses of IL-2 prevented the development of EBV-associated disease in severe combined immunodeficiency (SCID) mice reconstituted with peripheral blood cells from EBV-seropositive subjects (). Conversely, high doses of IL-2, by binding low-affinity receptors expressed on natural killer (NK) cells, may enhance several pro-inflammatory cytokines, and consequently B cell stimulation and activation (; ; Table 1).
Table 1
| Factors | Mechanism(s) | Reference | |
|---|---|---|---|
| HIV-1 proteins | Virions | Virions bind to B cells through CD21 and transmit infection to T cells | |
| gp120 | Binding to C-type lectins and induced immunoglobulin class switch recombination through a CD40-independent mechanism | ||
| Induction of TNF-α and hypergammaglobulinemia | |||
| gp120 (X4 strains) | Increased proliferation capability of EBV+ B cells | ||
| gp41 | Induced activation of IL-6 and IL-10 pro-inflammatory cytokines | Takeshita et al. (1995) | |
| Nef | Activation of B cells and induction of hypergammaglobulinemia through ferritin produced via Nef-mediated activation of NF-κB | Swingler et al. (2008) | |
| Suppression of CD40-dependent immunoglobulin class switching | |||
| Tat | Binding to Rb2/p130 and induction of cell cycle genes; modulation of cell cycle and increased proliferative capability of EBV+ B cells | ; | |
| PAMPs* | LPS | Engagement and activation of TLR4; induction of pro-inflammatory cytokines | |
| 16S rDNA, CpG DNA | Engagement and activation of TLR9; suppression of EBV lytic cycle through inhibition of BZLF expression | ; Zauner and Nadal (2012) | |
| DAMPs** | mtDNA | Engagement of TLR9 and suppression of EBV lytic cycle | Zhang et al. (2010) |
| HMGB1 | Engagement of TLR2 and TLR4; induction of pro-inflammatory cytokines |
Factors involved in HIV-1 and EBV interplay through B cell activation.
Pathogen-associated molecular patterns.
Damage-associated molecular patterns.
It has been demonstrated that patients with high levels of EBV have higher levels of pro-inflammatory cytokines (IL-6, IL-10, TNF-α) and PAMPs (LPS) than patients with low EBV level, and that EBV load strongly correlates with the percentage of activated B cells (). In addition, patients under CD4-guided interruption of ART to reduce adverse drug effects show similar levels of HIV-1 plasmaviremia to ART-untreated patients and high levels of EBV (). The association between markers of B cell activation and the risk of NHL persists even after adjustment for CD4 T cell count, HIV-1 load and ART, thus supporting the independent role of these markers with NHL risk (; ; ). These findings additionally support the concept that B cell activation, regardless of CD4 immune reconstitution, favors expansion of EBV-infected cells and the onset of EBV-related malignancies.
CONCLUDING REMARKS
The risk of EBV-associated NHL in HIV-1 infected patients compared with the general population is mainly increased by impaired immunosurveillance against EBV and B cell chronic immune activation. The two mechanisms may contribute to the development of NHL subtypes in different ways. In HIV-1 infected subjects with low CD4 T cell count and severe immunedepression, a notable proportion of NHL is represented by PCNSL. These tumors are almost 100% EBV-positive, are less significantly linked to circulating levels of pro-inflammatory cytokines than systemic NHL (), and represent the NHL subtype which most significantly declined after the introduction of ART. These observations are consistent with the concept that PCNSL primarily results from the loss of immunosurveillance against EBV.
Systemic HL may occur relatively early in HIV-1 disease and the impact of ART in reducing these tumors is lower than that observed for PCNSL and other ADC. Chronic immune activation may considerably affect the onset of systemic NHL; chronic B cell activation, generated by HIV-1 antigens and the products of microbial translocations, may result in expansion of B cells and accumulation of genetic lesions over a prolonged period of time. According to this model, EBV does not represent a prerequisite for systemic lymphomagenesis; unlike PCNSL, systemic lymphomas may also be EBV-negative. Nonetheless, the oncogenic properties of EBV play a critical role; EBV-infected B cells may overcome EBV-negative B cells due to the proliferating activity and activation of telomerase (Terrin et al., 2007, 2008; ); most systemic tumors are in fact EBV-positive (Figure 1). Current strategies to treat HIV-1 are efficient in decreasing HIV-1 plasmaviremia and restoring immune functions but may be not efficient enough in reducing immune activation (). The new strategies to treat HIV-1 should take into account this important parameter. The prevention of chronic immune activation may prevent the onset of EBV-related diseases.
FIGURE 1
Statements
Acknowledgments
This work was supported by the PENTA Foundation, and the Associazione Italiana per la Ricerca sul Cancro (AIRC).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
REFERENCES
1
AmbinderR. F.BhatiaK.Martinez-MazaO.MitsuyasuR. (2010). Cancer biomarkers in HIV patients.Curr. Opin. HIV AIDS5531–536.10.1097/COH.0b013e32833f327e
2
AnselmiA.VendrameD.RamponO.GiaquintoC.ZanchettaMDe RossiA. (2007). Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy.Clin. Exp. Immunol.150442–450.10.1111/j.1365-2249.2007.03526.x
3
AudigéA.SchlaepferE.von WylV.MillerR. C.VernazzaP.NadalD.et al (2010). B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering.AIDS Res. Hum. Retroviruses261063–1074.10.1089/aid.2009.0288
4
BaiocchiR. A.CaligiuriM. A. (1994). Low-dose interleukin 2 prevents the development of Epstein–Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 915577–5581. 10.1073/pnas.91.12.5577
5
BeralV.NewtonR. (1998). Overview of the epidemiology of immunodeficiency-associated cancers.J. Natl. Cancer Inst. Monogr.231–6.10.1093/oxfordjournals.jncimonographs.a024164
6
BerberianL.GoodglickL.KippsT. J.BraunJ. (1993). Immunoglobulin VH3 gene products: natural ligands for HIV gp120.Science2611588–1591.10.1126/science.7690497
7
BiggarR. J.ChaturvediA. K.GoedertJ. JEngelsE. A. HIV/AIDS Cancer Match Study. (2007). AIDS-related cancer and severity of immunosuppression in persons with AIDS.J. Natl. Cancer Inst.99962–972.10.1093/jnci/djm010
8
BlackburnE. H.GreiderC. W.SzostakJ. W. (2006). Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging.Nat. Med.121133–1138.10.1038/nm1006-1133
9
BlazevicV.HeinoM.LagerstedtA.RankiA.KrohnK. J. (1996). Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals.J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.13208–214.10.1097/00042560-199611010-00002
10
BreenE. C.HussainS. K.MagpantayL.JacobsonL. P.DetelsR.RabkinC. S.et al (2011). B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.Cancer Epidemiol. Biomarkers Prev.201303–13014.10.1158/1055-9965.EPI-11-0037
11
BrenchleyJ. M.PriceD. A.SchackerT. W.AsherT. E.SilvestriG.RaoS.et al (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection.Nat. Med.121365–1371.10.1038/nm1511
12
BurighelN.GhezziS.NozzaS.Del BiancoP.LazzarinA.TambussiG.et al (2006). Differential dynamics of Epstein–Barr virus in HIV-1 infected individuals receiving intermittent interleukin-2 and antiretroviral therapy.Haematologica91244–247.
13
CarboneA.CesarmanE.SpinaM.GloghiniA.SchulzT. F. (2009). HIV-associated lymphomas and gamma-herpesviruses.Blood1131213–1224.10.1182/blood-2008-09-180315
14
CattelanA. M.CalabròM. L.AversaM. L.ZanchettaM.MeneghettiF.De RossiA.et al (1999). Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.Eur. J. Cancer351809–1815.10.1016/S0959-8049(99)00161-6
15
ChenM. R. (2011). Epstein–Barr virus, the immune system, and associated diseases.Front. Microbiol. 2:5. 10.3389/fmicb.2011.00005
16
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. (2009). Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Antivir. Ther.141065–1074. 10.3851/IMP1462
17
ColombrinoE.RossiE.BallonG.TerrinL. Indraccolo, S., Chieco-BianchiL.et al (2004). Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein–Barr virus-immortalized B cells.Exp. Cell Res.295539–548.10.1016/j.yexcr.2004.01.018
18
DeekenJ. F.Tjen-A-LooiA.RudekM. A.OkuliarC.YoungM.LittleR. F.et al (2012). The rising challenge of non-AIDS-defining cancers in HIV-infected patients.Clin. Infect. Dis.551228–1235.10.1093/cid/cis613
19
DeeksS. G.KitchenC. M.LiuL.GuoH.GasconR.NarváezA. B.et al (2004). Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.Blood104942–947.10.1182/blood-2003-09-3333
20
De RossiA.OmettoL.RoncellaS.D’AndreaE.MeninC.CalderazzoF.et al (1994). HIV-1 induces down-regulation of bcl-2 expression and death by apoptosis of EBV-immortalized B cells: a model for a persistent “self-limiting” infection.Virology198234–244.10.1006/viro.1994.1026
21
DolcettiRDe RossiA. (2012). Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis:pathogenetic and clinical implications.Med. Res. Rev.32233–253.10.1002/med.20211
22
DraborgA. H.DuusK.HouenG. (2012). Epstein–Barr virus and systemic lupus erythematosus.Clin. Dev. Immunol.201237051610.1155/2012/370516
23
EngelsE. A.PfeifferR. M.LandgrenO.MooreR. D. (2010). Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era.J. Acquir. Immune Defic. Syndr.5478–84.10.1097/01.qai.0000371677.48743.8d
24
FranceschiS.LiseM.CliffordG. M.RickenbachM.LeviF.MaspoliM.et al (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study.Br. J. Cancer103416–422.10.1038/sj.bjc.6605756
25
FrankelA. D.PaboC. O. (1988). Cellular uptake of the tat protein from human immunodeficiency virus.Cell551189–1193.10.1016/0092-8674(88)90263-2
26
GiuncoS.DolcettiR.KeppelS.CeleghinA.IndraccoloS.Dal ColJ.et al (2013). hTERT inhibition triggers Epstein–Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.Clin. Cancer Res.192036–2047.10.1158/1078-0432.CCR-12-2537
27
GoedertJ. J.CotéT. R.VirgoP.ScoppaS. M.KingmaD. W.GailM. H.et al (1998). Spectrum of AIDS-associated malignant disorders.Lancet3511833–1839.10.1016/S0140-6736(97)09028-4
28
GougeonM. L.LecoeurH.DulioustA.EnoufM. G.CrouvoiserM.GoujardC.et al (1996). Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.J. Immunol.1563509–3520.
29
GrulichA. E. (2009). Living longer with HIV: what does it mean for cancer risk?Curr. Opin. HIV AIDS41–2. 10.1097/COH.0b013e32831c508a
30
GrulichA. E.WanX.LawM. G.MillikenS. T.LewisC. R.GarsiaR. J.et al (2000). B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS.AIDS14133–140.10.1097/00002030-200001280-00008
31
GuiguetM.BouéF.CadranelJ.LangJ. M.RosenthalE.CostagliolaD.et al (2009). Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.Lancet Oncol.101152–1159.10.1016/S1470-2045(09)70282-7
32
HazenbergM. D.StuartJ. W.OttoS. A.BorleffsJ. C.BoucherC. A.de BoerR. J.et al (2000). T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).Blood95249–255.
33
HeB.QiaoX.KlasseP. J.ChiuA.ChadburnA.KnowlesD. M.et al (2006). HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors.J. Immunol.1763931–3941.
34
HellersteinM. K.HohR. A.HanleyM. B.CesarD.LeeD.NeeseR. A.et al (2003). Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection.J. Clin. Invest.112956–966.10.1172/JCI17533
35
HongG. K.KumarP.WangL.DamaniaB.GulleyM. L.DelecluseH. J.et al (2005). Epstein–Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.J. Virol.7913984–13992.10.1128/JVI.79.22.13984-13992.2005
36
HuntP. W.BrenchleyJ.SinclairE.McCuneJ. M.RolandM.Page-ShaferK.et al (2008). Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.J. Infect. Dis.197126–133.10.1086/524143
37
International Collaboration on HIV and Cancer. (2000). Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.J. Natl. Cancer Inst.921823–1830.10.1093/jnci/92.22.1823
38
IyengarS.SchwartzD. H. (2011). Potentiation of EBV-induced B cell transformation by CXBR4-tropic, but not CBR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.AIDS Res. Hum. Retroviruses27519–523.10.1089/aid.2010.0131
39
JacobsonC. A.AbramsonJ. S. (2012). HIV-associated Hodgkin’s lymphoma: prognosis and therapy in the era of cART.Adv. Hematol.201250725710.1155/2012/507257
40
JacobsonL. E.PilaroF.SmithK. A. (1996). Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.Proc. Natl. Acad. Sci. U.S.A.9310405–10410.10.1073/pnas.93.19.10405
41
JanewayC. A.Jr.MedzhitovR. (2002). Innate immune recognition.Annu. Rev. Immunol.20197–216.10.1146/annurev.immunol.20.083001.084359
42
KaplanL. D. (2012). HIV-associated lymphoma.Best Pract. Res. Clin. Haematol.25101–117.10.1016/j.beha.2012.01.001
43
LadellK.DornerM.ZaunerL.BergerC.ZucolF.BernasconiM.et al (2007). Immune activation suppresses initiation of lytic Epstein–Barr virus infection.Cell. Microbiol.92055–2069.10.1111/j.1462-5822.2007.00937.x
44
LazziS.BellanC.De FalcoG.CintiC.FerrariF.NyongoA.et al (2002). Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin’s lymphomas: implications for disease pathogenesis.Hum. Pathol.33723–731.10.1053/hupa.2002.125372
45
MaS. D.HegdeS.YoungK. H.SullivanR.RajeshD.ZhouY.et al (2011). A new model of Epstein–Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.J. Virol.85165–177.10.1128/JVI.01512-10
46
MalaspinaA.MoirS.HoJ.WangW.HowellM. L.O’SheaM. A.et al (2006). Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7.Proc. Natl. Acad. Sci. U.S.A.1032262–2267.10.1073/pnas.0511094103
47
MalaspinaA.MoirS.NickleD. C.DonoghueE. T.OgwaroK. M.EhlerL. A.et al (2002). Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma.J. Virol.768855–8863.10.1128/JVI.76.17.8855-8863.2002
48
MalnatiM.BroccoloF.NozzaS.SarmatiL.GhezziS.LocatelliG.et al (2002). Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy.Blood1001575–1578.
49
MandlJ. N.BarryA. P.VanderfordT. H.KozyrN.ChavanR.KluckingS.et al (2008). Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections.Nat. Med.141077–1087.10.1038/nm.1871
50
MarksM. A.RabkinC. S.EngelsE. A.BuschE.KoppW.RagerH.et al (2013). Markers of microbial translocation and risk of AIDS-related lymphoma.AIDS27469–474.10.1097/QAD.0b013e32835c1333
51
MoirS.FauciA. S. (2009). B cells in HIV infection and disease.Nat. Rev. Immunol.9235–245.10.1038/nri2524
52
MoirS.MalaspinaA.LiY.ChunT. W.LoweT.AdelsbergerJ.et al (2000). B cells of HIV-1-infected patients bind virions through CD21 complement interactions and transmit infectious virus to activated T cells.J. Exp. Med.192637–646.10.1084/jem.192.5.637
53
OmettoL.MeninC.MasieroS.BonaldiL.Del MistroA.CattelanA. M.et al (1997). Molecular profile of Epstein–Barr virus (EBV) in human immunodeficiency virus type 1 (HIV-1)-related lymphadenopathies and lymphomas.Blood90313–322.
54
PalellaF. J.Jr.DelaneyK. M.MoormanA. C.LovelessM. O.FuhrerJ.SattenG. A.et al (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.HIV Outpatient Study Investigators. N. Engl. J. Med.338853–860.10.1056/NEJM199803263381301
55
PetoumenosK.van LeuwenM. T.VajdicC. M.WoolleyI.ChuahJ.TempletonD. J.et al (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).HIV Med.1477–84.10.1111/j.1468-1293.2012.01038.x
56
PetraraM. R.CattelanA. M.ZanchettaM.SassetL.FregujaR.GianesinK.et al (2012). Epstein–Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.J. Clin. Virol.53195–200.10.1016/j.jcv.2011.12.013
57
PowlesT.RobinsonD.StebbingJ.ShamashJ.NelsonM.GazzardB.et al (2009). Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.J. Clin. Oncol.27884–890.10.1200/JCO.2008.19.6626
58
QiaoX.HeB.ChiuA.KnowlesD. M.ChadburnA.CeruttiA. (2006). Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.Nat. Immunol.7302–310.10.1038/ni1302
59
RappoccioloG.PiazzaP.FullerC. L.ReinhartT. A.WatkinsS. C.RoweD. T.et al (2006). DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes.PLoS Pathog. 2:e70. 10.1371/journal.ppat.0020070
60
RegidorD. L.DetelsR.BreenE. C.WidneyD. P.JacobsonL. P.PalellaF.et al (2011). Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.AIDS25303–314.10.1097/QAD.0b013e32834273ad
61
RieckmannP.PoliG.FoxC. H.KehrlJ. H.FauciA. S. (1991). Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors.J. Immunol.1472922–2927.
62
RighettiE.BallonG.OmettoL.CattelanA. M.MeninC.ZanchettaM.et al (2002). Dynamics of Epstein–Barr virus in human immunodeficiency virus type 1-infected subjects on highly active antiretroviral therapy.AIDS1663–73.10.1097/00002030-200201040-00009
63
ScaffidiP.MisteliT.BianchiM. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.Nature418191–195.10.1038/nature00858
64
ScalaG.RuoccoM. R.AmbrosinoC.MallardoM.GiordanoV.BaldassarreF.et al (1994). The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.J. Exp. Med.179961–971.10.1084/jem.179.3.961
65
SchnittmanS. M.LaneH. C.HigginsS. E.FolksT.FauciA. S. (1986). Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus.Science2331084–1086.10.1126/science.3016902
66
SimardE. P.PfeifferR. M.EngelsE. A. (2011). Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States.Cancer1171089–1096.10.1002/cncr.25547
67
SørensenO. E.ThapaD. R.RosenthalA.LiuL.RobertsA. A.GanzT. (2005). Differential regulation of beta-defensin expression in human skin by microbial stimuli.J. Immunol.1744870–4879.
68
SparanoJ. A. (2001). Clinical aspects and management of AIDS-related lymphomas.Eur. J. Cancer371296–1305.10.1016/S0959-8049(01)00111-3
69
SwinglerS.ZhouJ.SwinglerC.DauphinA.GreenoughT.JolicoeurP.et al (2008). Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.Cell Host Microbe463–76.10.1016/j.chom.2008.05.015
70
TakeshitaS.BreenE. C.IvashchenkoM.NishanianP. G.KishimotoT.VredevoeD. L.et al (1995). Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line.Cell. Immunol.165234–242.10.1006/cimm.1995.1210
71
TerrinL.Dal ColJ.RampazzoE.ZancaiP.PedrottiM.AmmirabileG.et al (2008). Latent membrane protein 1 of Epstein–Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes.J. Virol.8210175–10187.10.1128/JVI.00321-08
72
TerrinL.DolcettiR.CorradiniI.IndraccoloS.Dal ColJ.BertorelleR.et al (2007). hTERT inhibits the Epstein–Barr virus (EBV) lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.Int. J. Cancer121576–587.10.1002/ijc.22661
73
TirelliU.BernardiD. (2001). Impact of HAART on the clinical management of AIDS-related cancers.Eur. J. Cancer371320–1324.10.1016/S0959-8049(01)00106-X
74
TitanjiK.De MilitoA.CagigiA.ThorstenssonR.GrützmeierS.AtlasA.et al (2006). Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.Blood1081580–1587.10.1182/blood-2005-11-013383
75
TyagiM.RusnatiM.PrestaM.GiaccaM. (2001). Internalization of HIV-1 Tat requires cell surface heparan sulphate proteoglycans.J. Biol. Chem.2763254–3256.10.1074/jbc.M006701200
76
YoungL. S.RickinsonA. B. (2004). Epstein–Barr virus: 40 years on.Nat. Rev. Cancer4757–768.10.1038/nrc1452
77
ZaunerL.NadalD. (2012). Understanding TLR9 action in Epstein–Barr virus infection.Front. Biosci. (Landmark Ed.)17: 1219–1231. 10.2741/3982
78
ZhangQ.RaoofM.ChenY.SumiY.SursalT.JungerW.et al (2010). Circulating mitochondrial DAMPs cause inflammatory responses to injury.Nature464104–107.10.1038/nature08780
Summary
Keywords
EBV, HIV-1, B cell activation, chronic immune activation, EBV-related malignancies, antiretroviral therapy, EBV lytic reactivation
Citation
Petrara MR, Freguja R, Gianesin K, Zanchetta M and De Rossi A (2013) Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front. Microbiol. 4:311. doi: 10.3389/fmicb.2013.00311
Received
09 May 2013
Accepted
28 September 2013
Published
18 October 2013
Volume
4 - 2013
Edited by
Mei-Ru Chen, National Taiwan University, Taiwan
Reviewed by
Mei-Ru Chen, National Taiwan University, Taiwan; Chi-Ju Chen, National Yang-Ming University, Taiwan
Copyright
© Petrara, Freguja, Gianesin, Zanchetta and De Rossi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anita De Rossi, Viral Oncology Unit and AIDS Reference Center, Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, 35128 Padova, Italy e-mail anita.derossi@unipd.it
This article was submitted to Virology, a section of the journal Frontiers in Microbiology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.